AN
Nguyen, Aude
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Increased incidence of blood culture contaminations during and after the COVID-19 pandemic | Infection |  | 2025 | 41 | 81 | ||
| Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas | Journal of antimicrobial chemotherapy | | 2025 | 45 | 48 | ||
| Combined resistance mechanisms leading to high-level of cefiderocol resistance among NDM-like producing E. coli ST167 clinical isolates | European journal of clinical microbiology & infectious diseases | | 2025 | 1 | 0 | ||
| Epidémiologie, facteurs de risque et outcomes des bactériémies pendant la période d’aplasie chez les receveurs de greffe de cellules souches hématopoïétiques | | 2025 | 85 | 335 | |||
| Epidemiology of hospital-acquired bloodstream infections in haemato-oncology patients in Geneva, Switzerland | Infection | | 2025 | 31 | 83 | ||
| Increase in PVC-BSI during the second COVID-19 pandemic year : analysis of catheter and patient characteristics | Antimicrobial resistance and infection control | | 2024 | 57 | 83 | ||
| Microbiology of catheter associated bloodstream infection : differences according to catheter type | International journal of infectious diseases | | 2024 | 52 | 96 | ||
| In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022 | European journal of clinical microbiology & infectious diseases | | 2024 | 57 | 104 | ||
| Potent in-vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates | Clinical microbiology and infection |  | 2024 | 101 | 1 | ||
| Impact of intermittent versus continuous infusions on central line-associated bloodstream infection risk in haemato-oncology patients : a quasi-experimental study | Journal of hospital infection | | 2024 | 53 | 168 | ||
| Pre-engraftment bacteremia after allogeneic hematopoietic cell transplantation without primary fluoroquinolone antibacterial prophylaxis | Transplant infectious disease | | 2024 | 61 | 96 | ||
| Controlling the hospital aquatic reservoir of multidrug-resistant organisms : a cross-sectional study followed by a nested randomized trial of sink decontamination | Clinical microbiology and infection | | 2024 | 163 | 129 | ||
| Postpartum septic arthritis of pubic symphysis due to Sneathia sanguinegens, Sneathia vaginalis, and Mageeibacillus indolicus : Contribution of clinicalmetagenomics | New microbes and new infections | | 2023 | 248 | 122 | ||
| Increased Peripheral Venous Catheter Bloodstream Infections during COVID-19 Pandemic, Switzerland | Emerging infectious diseases | | 2023 | 120 | 228 | ||
| Hepatitis C treatment program in Maputo, Mozambique, the challenge of genotypes and key populations : A 5-year retrospective analysis of routine programmatic data | Health science reports | | 2023 | 94 | 42 | ||
| Epidemiological characteristics and real-world treatment outcomes of hepatitis C among HIV/HCV co-infected patients in Myanmar : A prospective cohort study | Health science reports | | 2023 | 69 | 54 | ||
| Prevention of mother-to-child transmission of hepatitis B virus in antenatal care and maternity services, Mozambique | Bulletin of the World Health Organization | | 2022 | 70 | 49 | ||
| Letermovir for cytomegalovirus primary prophylaxis in a multiple abdominal/small bowel transplant recipient | Clinical transplantation | | 2022 | 254 | 0 | ||
| Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar | BMJ global health | | 2021 | 80 | 39 | ||
| Fièvre d’origine indéterminée : cheval, zèbre ou licorne ? | Revue médicale suisse | | 2021 | 86 | 271 | ||
| HCV genetic diversity can be used to infer infection recency and time since infection | Viruses | | 2020 | 228 | 93 |
